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Childrenthatundergotreatmentforcancerareatriskofsuﬀeringfromsubfertilityorhormonaldysfunctionduetothedetrimental
eﬀectsofradiotherapyandchemotherapeuticagentsonthegonads.Cryopreservationofovariantissuepriortotreatmentoﬀersthe
possibility of restoring gonadal function after resumption of therapy. Eﬀective counseling and management of pediatric patients
is crucial for preserving their future reproductive potential. The purpose of this article is to review recent literature and to revise
recommendations we made in a 2007 article. Pediatric hemato-oncology, reproductive endocrinology, surgery, anesthesia and
bioethics perspectives are discussed and integrated to propose guidelines for oﬀering ovarian cryopreservation to premenarcheal
girls with cancer.
1.Introduction
Ovarian cryopreservation has been oﬀered to patients for
more than a decade and, to date, more than 15 babies
have been born worldwide after successful transplantation of
ovarian tissue [1, 2]. The success of ovarian cryopreservation
in adult women at risk for infertility secondary to exposure
to chemotherapy and radiation therapy has led pediatric
oncologists to consider ovarian tissue cryopreservation in
prepubertal girls undergoing potentially gonadotoxic ther-
apy. However, oﬀering ovarian cryopreservation to young
girls raises major medical, ethical, and legal issues unique to
this age group that must be addressed. Firstly, the eﬃcacy
of the procedure in this setting is unclear, and it remains
to be shown that ovarian tissue harvested from prepubertal
girls can yield a successful pregnancy when retransplanted
after puberty. Secondly, identifying the patients most likely
to beneﬁt from the procedure is complex, because of the
diﬃculty in evaluating the risk for fertility impairment in
young patients, especially when the time interval between
administration of chemotherapy and clinical presentation of
premature ovarian insuﬃciency is measured in years [3].
Lastly, since preservation procedures must be performed
soon after diagnosis, while the patient herself is not old
enough to provide informed consent, there are bioethical
concerns regarding the validity of the process. The purpose
of this article is to review recent literature and to revise our
recommendations from the article published in 2007 [4].
2.PediatricHematology-Oncology
Perspective
In 2010, a total of 10,700 children and adolescents under
the age of 14 were diagnosed with cancer in the US alone.
More than 80% will survive the disease [5]. For some2 Obstetrics and Gynecology International
common pediatric cancers such as Wilms’ tumor, Hodgkin’s
disease (HD), and B-cell non-Hodgkin lymphoma (B-NHL)
cure rates approach 90% [6] .T h e s eh i g hc u r er a t e sr e s u l ti n
a growing number of children who will become long-term
cancer survivors [7]. However, survivors often face long-
termsequelaeoftheirtreatmentbecauseofirreversibletissue
damage including to the reproductive organs that may harm
pubertal development. Alternatively, they may present in
adulthood with infertility or premature menopause, deﬁned
as cessation of ovarian function below the age of 40 [3].
Clearly,removalofthereproductiveorgansduringtreatment
of a malignancy will prevent patients from conceiving with
their own gametes. However, chemotherapy and radiother-
apy may also eliminate or severely compromise hormonal
p r o d u c t i o n ,a sw e l la sap a t i e n t ’ sr e p r o d u c t i v ep o t e n t i a l ,b y
damaging steroid-producing cells and gametes.
2.1. Eﬀect of Chemotherapy on Reproductive Potential. Both
female and male gonadal tissues are very sensitive to chem
otherapy [8, 9] .T h ed e g r e eo fd a m a g ei sd e t e r m i n e db yt h e
patient’s sex and age, as well as the drug used and the dose
administered [10, 11].
Some pediatric chemotherapy regimens such as MOPP
(mustragen,oncovin,procarbazine,andprednisone)forHD,
and high-dose cyclophosphamide and busulfan for bone
marrow transplantation, cause sterility in a signiﬁcant
number of patients [12–16]. Other regimens such as high-
dose cyclophosphamide for B-NHL and Ewing sarcoma are
associated with a signiﬁcant risk for fertility impairment. No
comprehensive data exists on the exact rates of fertility im-
pairment associated with current pediatric oncology thera-
peutic regimens.
All chemotherapeutic drugs aﬀect gonadal function
although some are considered more harmful than others
[17]. For example, alkylating agents such as cyclophos-
phamide and procarbazine are categorised as high-risk drugs
[8, 18], whereas vincristine and methotrexate are considered
to have lower risks. The problem, however, when trying to
advise patients and their parents is that most patients are
treated with multiagent protocols, and the relative contribu-
tion of individual drugs is diﬃcult to determine. Hence, it
is virtually impossible to give the patient or his/her parents
an accurate assessment of the risk to fertility, but rather the
patients are considered to be at a low, intermediate, or high
risk of infertility [19, 20].
2.2. Eﬀect of Radiation on Reproductive Potential. Total-
body irradiation (TBI) or radiation therapy delivered to the
pelvis/abdomen may cause irreversible damage to the gon-
ads.Inbothsexes,thedegreeofdamagedependsontheradi-
ation dose and ﬁeld, fractionation schedule, and the patient’s
age. In females, it has been shown that for a given dose of
radiation, the younger the patient at the time of treat-
ment, the later the onset of premature menopause is [21].
A radiation dose of 2Gy is estimated to damage 50% of
ovarian follicles irreversibly; doses ranging from 5 to 20Gy
cause complete loss of ovarian function resulting in sterility
[22].
2.3. Reduction of Treatment-Related Gonadotoxicity. Several
approaches have been developed to reduce treatment-related
gonadotoxicity. The ideal approach is to design treatment
regimens that will maintain high cure rates while decreas-
ing or eliminating agents with signiﬁcant tissue toxicity.
However, despite a growing understanding of the biology of
cancer, and the identiﬁcation of molecular targets speciﬁc to
the malignant cell, the concept of targeted therapy, aﬀecting
only the malignant clone and sparing normal tissues, is still,
in clinical practice, the exception rather than the rule
and most survivors of childhood cancer are still at risk
for signiﬁcant long-term side eﬀects including eﬀects on
fertility.
Another approach to decreasing the risk to fertility is the
use of gender-tailored therapy. Boys with HD, who are more
susceptible to the sterilizing eﬀects of chemotherapy, are
treated with lower doses of chemotherapy combined with
radiation. Conversely, girls, who have a prohibitively high
risk of radiation-induced secondary malignancies (especially
breast cancer) and are less prone to chemotherapy-induced
gonadal damage, are treated with more intensive chemother-
apy but without radiation when feasible [23, 24].
Reduced chemotherapy and/or radiation therapy in dis-
eases with high cure rates such as HD is conceptually appeal-
ing and may be eﬃcacious. This approach, however, is not
feasible in many pediatric malignancies. For example, high-
risk acute lymphoblastic leukemia, neuroblastoma, Ewing
sarcoma, high-risk rhabdomyosarcoma, and high-grade B-
cell lymphoma are all treated with dose-intensive schedules
that rely heavily on the use of alkylating agents [25–28].
Treatment regimens for these cancers have not changed
signiﬁcantly in the last decade and most patients treated
with these regimens are expected to become long-term
survivors, and to experience signiﬁcant gonadal damage.
Female patients with stage III Wilms’ tumor who receive
whole-abdomen radiation therapy are also at a high risk
for fertility impairment [29]. Unfortunately, it is unlikely
that these regimens will be supplanted in the foreseeable
futurebyequallyeﬀectivebutlessgonadotoxicregimens.The
same applies to pediatric patients undergoing bone marrow
transplantation, the overwhelming majority of whom will
developgonadalfailure[30].Therefore,itisvitallyimportant
to develop eﬀective approaches to fertility preservation that
may be oﬀered to preadolescent children who are about to
receive cancer treatment that is associated with a high risk of
gonadal damage.
3.ReproductiveEndocrinologists’Perspective
In adult patients that have a partner, cryopreservation of
embryos remains the most reliable method to preserve fer-
tility [20]. Another eﬃcient option is vitriﬁcation of mature
unfertilized oocytes [31]. Both these methods require hor-
monalstimulationanddelayoftreatment,thuscannotbeof-
feredtoyounggirlsorpatientsthatmustreceiveurgenttreat-
ment. Cryopreservation of gonadal tissue can now be oﬀered
to patients with malignancies that require gonadotoxic ther-
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3.1. Indications for Ovarian Tissue Cryopreservation. As the
extentoftheinsulttogonadalfunctionvariesacrossdiﬀerent
diseases and treatment protocols, it is important to counsel
patients eﬀectively about their risk of infertility. A classiﬁca-
tion system has therefore been developed, which lists most
malignant diseases and their associated treatments [32].
However, the precise course of any disease is never com-
pletely predictable despite the best attempts to estimate
prognosis prior to treatment. For example, in a series of 58
girls<16yearsold,Jadouletal.showedthat14%,whoinitial-
ly received treatment that placed them at low- to-medium
risk of premature ovarian failure, needed more aggressive
gonadotoxic treatment in the months following cryopreser-
vation [33].
Benign indications for fertility preservation procedures
include haematological or autoimmune diseases, as well as
certain genetic conditions such as Fragile-X and Turner
syndrome which predispose women to premature ovarian
failure. In addition, repeated surgery due to ovarian cysts or
ovarian torsion may result in decreased ovarian reserve [33].
3.2. Ovarian Tissue Cryopreservation. The procedure of
ovarian tissue cryopreservation consists of several steps
following the harvesting of the tissue. After harvesting,
ovarian tissue is promptly delivered to the laboratory.
Aspiration of any follicles present should be performed
before cryopreserving ovarian tissue. Immature oocytes
obtained from premenarchal girls can be matured in vitro
andcryopreservedforfuturefertilization[34].Ovariantissue
is traditionally cryopreserved using a “slow freezing” method
[35]. First, ovarian cortex is separated from the medulla. The
cortex is then dissected into small fragments, to maximize
permeationofcryoprotectiveagentsintothecells;thesemust
be used to protect the oocyte and surrounding stromal cells
from freezing injuries [36]. Ovarian fragment size ranges
between 5mm [1] and 350µm in thickness [2]. The exact
composition of the cryoprotective solution and the freezing
protocol vary between institutions [37, 38]. Most commonly,
the solutions contain permeating cryoprotectants such as
dimethyl sulfoxide (DMSO), 1,2-propanediol, or ethylene
glycol, in combination with nonpermeating substances such
as sucrose and human serum albumin. Tubes containing
immersed ovarian tissue fragments are gradually cooled
by a programmable freezer that allows slow and stepwise
decreases in temperature. When the temperature reaches
−140◦C, the tubes can be plunged into liquid nitrogen at
−196◦C for storage.
3.3. Experimental Techniques for Ovarian Tissue Storing. A
recent and promising technique for storing ovarian tissue is
“rapid freezing,” termed vitriﬁcation. Small ovarian cortical
fragments are immersed for a short period in a highly
concentratedcryoprotectivesolution.Withoutaslowcooling
delay, the ovarian tissue is plunged directly into liquid
nitrogen. This induces a glass-like state that avoids the
formation of ice crystals, which may harm the oocyte and
stromal cells. The eﬃciency and safety of the technique still
need to be fully investigated before it becomes standard
practice. It has been suggested that vitriﬁcation is superior
to slow freezing in terms of follicular survival and tissue
preservation in general [39, 40]. Others have reported that
conventional freezing is a more suitable method for ovarian
tissue cryopreservation than vitriﬁcation [41, 42]. Currently,
new vitriﬁcation protocols are being developed and may
achieve better results [43]. Cryopreservation of an intact
ovary is challenging because cryoprotective agents cannot
penetrate all cells equally. The vascular pedicle of the ovary
must be harvested and carefully dissected, but it can be
diﬃcult to avoid damaging the ovarian vessels. The ovarian
artery is usually perfused, via a catheter, with a heparinised
physiological solution so as to drain all the blood from the
ovary. Thereafter, the ovary is perfused by, and immersed in,
acryoprotectivesolutionfollowedbyacoolingprocess,using
a slow freezing protocol, as described above [44].
3.4. Transplantation of Ovarian Tissue. Autotransplantation
of ovarian tissue once the patient is well enough can
take place in several anatomical sites: the normal ovarian
(orthotopic site) or another (heterotopic site) location.
Regardless of the site, transplantation of ovarian tissue
fragments is performed without any vascular anastomosis
as the tissue is sutured directly to the recipient site.
Orthotopic transplantation is performed in or onto the
remaining ovary or ovarian stump, or by transplanting the
tissue into a peritoneal pocket created by the surgeon in
the broad ligament or pelvic peritoneum of the ovarian
fossa. Transplantation can be performed at laparoscopy
[45] or laparotomy [46]. In the presence of intact and
patent fallopian tubes, spontaneous conception has been
reported after orthotopic transplantation [45]. Alternatively,
oocytes can be aspirated from the transplanted tissue for
IVF [47]. Successful transplantation of ovarian tissue has
not yet been described in paediatric patients, mainly because
the cryopreservation and transplantation techniques are
relatively new. However, we can assume that signiﬁcant
numbers of patients will undergo transplantation in the
near future given that harvesting and cryopreservation of
ovarian tissue has been performed in children for more
than a decade. In adults, 14 healthy babies have been
born after autotransplantation of cryopreserved ovarian
tissue (see review by [1, 2]). These results suggest that the
harvesting, cryopreservation, storage, and transplantation
procedures are both feasible and safe. Ovarian tissue in
children is rich in primordial follicles that appear to survive
the cryopreservation and transplantation insults well. Abir
et al. showed that ovarian biopsy from a 5-year-old patient
contained viable follicles after cryopreservation that were
suitable for transplantation [48]. The tissue harvested from
young children is therefore expected to yield positive results
after transplantation. A work in mice that analysed ovarian
function after transplantation of immature ovarian tissue
demonstrated that immature ovarian grafting can restore
spontaneous puberty and fertility [49]. All live births that
have resulted from ovarian tissue transplantation have arisen
from orthotopic sites. Heterotopic transplantation can be to
any site in the body other than the ovary or the adjacent
peritoneum, for example, the subcutaneous space of the
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have been proposed include the uterus, rectus abdominal
muscle, and the space between the breast and superﬁcial
fascia of the pectoralis muscle [52]. Clearly, spontaneous
conception is impossible at such sites, and IVF treatment
is required. The advantages of using heterotopic sites are
that the transplantation procedure is easier and the oocytes
are more accessible for aspiration during IVF treatment.
However, no clinical pregnancies have been achieved from
heterotopic sites even though ovarian function has been
restored [51]. Whole ovary can be transplanted through
microsurgical anastomosis of the ovarian vessels to a recipi-
entsite,eitherheterotopicororthotopic.Althoughsuccessful
transplantation of a frozen-thawed whole ovary has not
yet been described in humans, encouraging data have been
published in sheep [53]. In humans, a successful pregnancy
was achieved following a microsurgical anastomosis of an
intact fresh ovary [54]. Several sites for transplantation have
been proposed, including the deep inferior epigastric, and
the deep circumﬂex iliac, pedicles [55]. The optimal site for
transplantation remains to be determined in further studies.
3.5. Risks in Ovarian Tissue Transplantation. The biggest
drawback to ovarian tissue transplantation, carried out
without a vascular anastomosis, is that the graft may not
survive. In the immediate period after transplantation there
may be ischaemic damage to the tissue, resulting in massive
follicular death; however, most primordial follicles survive
this ischaemic insult [36, 56]. Surgical manipulations have
been described to encourage prompt neovascularisation of
the transplanted tissue, for example, a two-step procedure,
involving the creation of granulation tissue one week
before orthoptic transplantation, is believed to decrease the
ischaemic damage [45]. Transplantation of a whole ovary
with its vascular pedicle clearly avoids such an ischaemic
period, as immediate reperfusion of the ovary should
occur: in sheep, hormonal function is reported to have
continued for 6 years following transplantation of whole
ovaries [57]. The only other major risk of transplantation
is the possibility of seeding malignant cells by reintroducing
ovariantissuecontainingmicrometastases,asrecentlyshown
through quantitative reverse-transcribed polymerase chain
reaction (RT-PCR) studies. In cryopreserved ovarian tissue
fromleukaemiapatients,RT-PCR,andlong-termxenotrans-
plantation detected malignant cells, which had been missed
histologically [58]. This risk is more evident in patients with
hematological malignancies [59], but cannot be excluded in
patients with solid tumors as well. For this reason, molecular
studies are recommended prior to transplanting the tissue;
long-term followup is also advisable to monitor for disease
recurrence.
Success in molecular detection of malignant cells
depends on the precise diagnosis and presence of genetic
markers. In chronic myeloid leukemia (CML) the presence
of BCR-ABL gene is characteristic and always allows for
detection of leukemic cell contamination in ovarian tissue.
In B- and T-cell lymphomas, as well as in acute leukemia
(ALL), PCR for immunoglobulin and T-cell receptor gene
rearrangements can be performed. Unfortunately, not all
cases display a speciﬁc genetic marker that can be detected
on PCR [59]. Histology and immunohistochemistry were
unable to locate malignant cells within the cryopreserved
ovarian tissue, and thus cannot be considered suﬃcient
testing prior to transplantation [58, 60].
3.6. Function of Ovarian Tissue Graft. Ovarian activity
usuallyreturnsapproximately4monthsaftertransplantation
[1]. This period corresponds to the time it takes for
primordial follicles, which are the ones that principally
survive freezing and the insult of transplantation, to mature
into antral follicles. Ovarian activity is conﬁrmed by tracking
follicular development with ultrasound, detecting ovulation
and measuring circulating sex hormones.
4. Pediatric Surgery Perspective
Ovarian cryopreservation involves the surgical harvesting of
ovariantissue.Animportantprerequisiteforperformingthis
procedure is a critical appraisal of the feasibility and safety of
ovarian surgery in children. Pathological conditions of the
ovary are encountered in infancy and childhood. Ovarian
cysts, torsion, or masses, can be treated surgically in infancy
and even the in neonatal period when indicated [61, 62].
4.1. Minimally Invasive Surgery. Over the last decade opera-
tiveendoscopyandtheconceptofminimallyinvasivesurgery
has changed the practice of surgery. Following improvement
and miniaturization of the required equipment, pediatric
surgeons adopted laparoscopic and thoracoscopic surgery
[63–65]. Laparoscopy has the advantage of exploring the
abdominal cavity through a small incision, evaluating both
ovaries before resection for fertility preservation. Laparo-
scopic oophorectomy is performed by isolating the fallopian
tube from the ovary and gaining control of the ovarian blood
supply. The ovary can be removed in a special bag through
one of the trocar sites or a small lower abdominal incision. It
isimportanttoavoidusingelectrocoagulationontheovarian
surface to preserve the cortical tissue that contains follicles.
The reported rate of complications is very low [66]. When
performed by experienced surgical and anesthetic teams,
oophorectomy for fertility preservation either by laparotomy
or by laparoscopy, can be done with minimal complications.
The emerging technique of single port-laparoscopy
requires a single umbilical incision rather than the standard
3-4 incisions and thus may improve cosmetic outcome
[67, 68]. Due to the novelty of the technique, there is
limitedexperienceinchildren. Therefore,webelieve thatthis
surgical technique can be oﬀered in selected cases [69].
4.2. Experience in Ovarian Tissue Cryopreservation in Chil-
dren. We estimate that several thousands of women world-
wide have undergone ovarian tissue cryopreservation. A
recent publication from Denmark’s registry, reports 18%
of patients younger than 14 years of age [37]. Donnez
and Dolmans reported successfully performed ovarian tissue
cryopreservation in 59 girls under 16 years of age without
complications [70]. In our program, about 15% of the
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under the age of 15 (see Table 1). We report no surgical
complications in pediatric patients. None of the procedures
had to be converted to open laparotomy.
In the future, laparoscopic harvesting of the whole ovary
including its vascular pedicle may be performed with the
prospect of subsequent microvascular anastomoses of the
ovarian vessels [44, 54]. It is important to take special care
to resect the full length of the infundibulopelvic ligament,
as it is crucial for the cryopreservation and transplantation
procedures.
5.PediatricAnesthesiology Perspective
Any anesthetic is associated with a risk of complications.
Anesthetic complications may increase in the presence of
additional risk factors due to either the subject’s condition
or the surgical procedure to be performed. These need to be
oﬀsetagainstthebeneﬁtthatisconferreduponthepatientby
the surgery or the risks to the patient of withholding surgery.
5.1. Beneﬁt to the Patient. Although fertility preservation
is not a life-saving procedure, fertility is in many patients’
eyes the very essence of life and many patients are prepared
to take signiﬁcant risks in order to become pregnant. The
discussion in this case is more complicated as the patients
are children, the surgery is still experimental (albeit with
extremely promising results) and fertility is not guaranteed.
These factors will be discussed in greater depth in the
next section; but if joint discussion between parents and
the multidisciplinary medical team suggest that there is a
genuine potential for fertility preservation, we feel that this
justiﬁes anesthetic risk in most cases. Sadly, this is usually
one of many anaesthetics that these children will need and
the oﬀer of hope of fertility is an important component in
their holistic care. Our primary focus in this section is on
assessing anesthetic risk factors.
5.2. The Eﬀect of Age on Anesthetic Risk. Anesthesia-related
complications remain more common in pediatric patients
than in adults. Currently, there are no clear guidelines
regarding the appropriate age to harvest ovarian tissue.
We previously suggested that harvesting should not be
performed in girls under the age of 3 because of anaesthetic
considerations [4]. However, Poirot et al. have reported a
large series of paediatric patients who underwent ovarian
tissueharvesting:13outof47were<3yearsold,theyoungest
of them being 10 months old at the time of the surgery [71].
The majority of intraoperative anesthetic complications
in children are respiratory complications, and intraoperative
laryngospasm is among the most common and important of
these. In a retrospective study of 130 cases of intraoperative
laryngospasm over 10 years in one large institution, 57%,
68%, and 83% of laryngospasm were recorded in children
younger than 3, 5, and 10 years old, respectively [72]. In a
prospectivestudyof24165anestheticsoveratwoyearperiod,
theincidenceofadverserespiratoryeventsper1000anesthet-
icsincreasedwithreducingage(<1year:36.1;1–7years:15.3;
8–15 years: 8.6) [73]. A prospective study of 9297 pediatric
anesthetics in a large single medical center also reported
that older children were less likely to have laryngospasm
and other perioperative respiratory adverse events (cough,
desaturation, or airway obstruction) than were younger
children [74]. However, there was no particular age cutoﬀ
thatwasassociatedwithastep-wisechangeinanestheticrisk.
Furthermore, that study showed only very modest eﬀects
of age on the risk for perioperative laryngospasm (RR 0.9;
95%CI 0.88–0.91; P<0.0001); the relative risk decreased
by 11% for each yearly increase in age. However, as the
baseline probability for perioperative laryngospasm was only
2% (and only 8% in the highest risk patients), the impact
on the incidence of perioperative laryngospasm is actually
very small. The impact of age on perioperative desaturation
(RR 0.95; 95%CI 0.94–0.96; P<0.0001) was even smaller
and there was no signiﬁcant eﬀect of age on perioperative
bronchospasm (RR 0.99; 95%CI 0.96–1.02; P = 0.33). By
contrast, the risk for perioperative laryngospasm increased
markedly if a nonspecialist anaesthesiologist was managing
the case (RR 3.85; 95%CI 2.47–5.98; P<0.0001), if
inhalation (rather than intravenous) induction was used
(RR 2.38; 95%CI 1.79–3.17; P<0.0001) and if there was
anesthesia change-over during the case (RR 4.09; 95%CI
2.65–6.34; P<0.0001).
From the balance of data currently available we feel that
the 3-year-age cutoﬀ is excessively conservative. Although
this was appropriate when the procedure was more experi-
mental, we would not now withhold anesthesia for laparo-
scopic oophorectomy for any child over the age of 1 year
based solely on age without any other anesthetic risk factors.
Below 1 year of age, each case should be assessed individually
and should warrant careful multidisciplinary discussion,
but here too, age alone should not be the overriding
consideration.
5.3. Other Anesthetic Risk Factors. Operative laparoscopy in
children [65, 75] involves the insuﬄation of carbon dioxide
into the peritoneal cavity to a preset pressure, typically 13cm
H2O. This is associated with several physiological challenges,
including impaired venous return, hypotension, impaired
respiratory compliance and hypercarbia. The eﬀects on
respiratory compliance are accentuated by the usual steep
head-down position. However, these eﬀects are limited to
the duration of gas insuﬄation, which is typically brief and
whichmaybecurtailedorappliedintermittentlyifnecessary.
Clearly this procedure is not oﬀered in healthy children
and a wide range of haematological and oncological diag-
noses will be present, each with their own spectrum of infec-
tious, metabolic, and respiratory complications. Where pos-
sible these all require optimization prior to surgery. In cases
of marked respiratory compromise (including pneumonia,
pleural eﬀusions, tense ascites, or hepatosplenomegaly) the
added physiological burden of operative laparoscopy may be
hazardous.
5.4. Balancing Risk and Beneﬁt. It is advisable to combine
ovarian tissue harvesting with other imaging or surgical
procedures that require anaesthesia, such as bone marrow
aspiration, lumbar puncture, or central line insertion [4].6 Obstetrics and Gynecology International
Table 1: Ovarian cryopreservation in pediatric patients, Hadassah Medical Center (1997–2011).
Patient Age at cryo (years) Diagnosis No. oocytes retrieved No. oocytes frozen
1 15 Ewing sarcoma 0 0
2 15 Thalassemia major 0 0
3 15 Osteosarcoma, cervical cancer 18 2
41 5 A M L 5 0
5 14 Ewing sarcoma 16 6
6 14 Rhabdomyosarcoma 5 3
7 13 Hodgkin’s disease 0 0
8 13 Non-Hodgkin’s lymphoma 0 0
9 13 Osteosarcoma 0 0
10 13 Hodgkin’s disease 2 2
11 13 Ewing sarcoma 9 5
12 13 Hodgkin’s disease 13 5
13 12 Ewing sarcoma 23 9
14 10 Sarcoma 0 0
15 10 Osteosarcoma 17 8
16 9 Osteosarcoma 6 2
17 8 Ewing sarcoma 8 2
18 5 Wilms’ tumor 7 1
19 3 Neuroblastoma 4 1
20 3 Rhabdomyosarcoma 0 0
Nevertheless, laparoscopy imposes additional physiological
challenges on the patient, and it is strongly advised to
correct hematological, infectious, and metabolic derange-
ments where possible prior to surgery and to optimize the
child’s respiratory and volume status. We would recommend
considering withholding the procedure from children with
markedly compromised respiratory function. Laparoscopic
oophorectomy should be performed by a surgical team with
appropriate training and equipment [76] and that includes
an anesthesiologist with specialist training in pediatric
anesthesia.
6.BioethicsPerspective
Fertility preservation in young girls through ovarian-
tissue cryopreservation is still considered experimental and
requires a procedure that involves certain risks. At the same
time, with a number of pregnancies and deliveries already
obtained by this method, it does provide young girls with a
real potential beneﬁt. A bioethical analysis should, therefore,
address the ethical obligation of clinicians to oﬀer this
alternative and to discuss it with their patients as well as the
ethical prerogative of parents to make this decision on behalf
of their daughter.
The ethical principles of beneﬁcence and respect for
patient autonomy are usually interpreted in the bioethics
literature as entailing an obligation to disclose any medical
information that is pertinent to the patient’s ability to make
informed decisions, particularly when such information is
directly related to a potential beneﬁt [77]. Applying these
principles can be relatively uncomplicated regarding medical
procedures that are already accepted as the standard of care.
It becomes more complicated regarding procedures that are
still considered by most to be experimental and when the
risk-beneﬁt ratio is unclear.
While ovarian-tissue cryopreservation is still considered
experimental, it can be argued that even at present, clinicians
have an ethical obligation to inform their patients of its
existence and discuss it with them. First, in terms of risk-
beneﬁt analysis, the risks are small while the beneﬁts are
signiﬁcant. The procedure does not require delaying cancer
treatment and the risk of general anesthesia can be miti-
gated by performing it during another medically indicated
anesthetic session. On the other hand, it oﬀers a tremendous
potential beneﬁt considering how devastating infertility can
be later in life. Second, the bioethics literature encourages
clinicians to acknowledge the “speciﬁc informational needs”
of patients [77]. Considering this is currently the only option
to preserve fertility in prepubertal girls and considering the
irreversibility of the situation, it can be argued that patients
have a speciﬁc need to be informed.
Do parents (or other legal guardians) have an ethical
prerogative to make a decision regarding ovarian-tissue
cryopreservation on behalf of their daughter? Parents have
an ethical obligation to make decisions that are in the best
interest of their child and they lose their parental liberty if
they do not. In this case, to evaluate their girl’s best interest
they need to consider her present interest in minimizing risk
against her future interest in fertility preservation. Since the
risk involved in the procedure is small, the crucial factor is
the nature of the girl’s interest in fertility preservation.
A child’s right to fertility preservation has been acknowl-
edged in the bioethics literature as a “right in trust,” a unique
type of right that ought to be safeguarded until the childObstetrics and Gynecology International 7
reachesadulthoodbutcanbeviolatedbeforethechildiseven
in a position to exercise it [78]. Davis claims that “therefore
the child now has the right not to be sterilized, so that
she may exercise the right to have children in the future”
[79].Sinceparentsareauthorizingcancertreatmentthatmay
impact future fertility, it is clear that they have the ethical
prerogative to consent to ovarian-tissue cryopreservation
whichistheonlywayofprotectingthis“rightintrust.”When
the patient has already reached an age at which it is possible
to explain to her the procedure’s purpose, it is of course
preferable to obtain her own assent as well.
7.Synthesisand Summary
The majority of children diagnosed with cancer are expected
to be cured and become long-term survivors. A substantial
number of these survivors are expected to face impaired fer-
tility secondary to the gonadotoxic eﬀects of chemotherapy
and radiation. Pretreatment fertility counselling and fertility
preservation have great impact on quality of life of cancer
survivors [80].
Cryopreservation of female gametes is considered eﬃ-
cacious using vitriﬁcation techniques [31]. However, this
requires hormonal stimulation and transvaginal aspiration
of oocytes—both are not applicable in young girls.
During the last years, most medical centres have opened
programs that oﬀer various fertility preservation strategies.
The American Society of Clinical Oncology (ASCO) has
established practice guidelines—however, these are not spe-
ciﬁc for children [81].
We currently recommend that all girls planned for
radiotherapy or chemotherapy be referred for consultation
by physicians specializing in fertility preservation. Fertility
preservation procedures should be oﬀered only after a
detailed discussion and informed consent process with the
parents, and, where age appropriate, with the child herself.
The experimental nature of the procedure should be clearly
stated along with presentation of potential beneﬁts. A multi-
disciplinary team including pediatric oncologists, reproduc-
tive endocrinologists, pediatric surgeons, and anesthetists, as
well as social workers, must work closely together to provide
optimal counselling for patients and their parents. The
decision on whether to perform oophorectomy or biopsies
of ovarian tissue depend on the patient’s age, treatment
gonadotoxicity, and physician’s preferences. The approach
shouldbediscussedwiththepatient/parentspriortosurgery.
Although we previously [4] recommended a lower limit
of age: 3 years old, we currently consider that ovary
cryopreservation can be safely oﬀered even to younger girls
since the potential beneﬁts are currently more evident and
the risks of anesthesia appear not to be increased. To provide
an additional margin of safety, we propose that if another
necessary medical or surgical procedure is planned (e.g.,
insertion of an indwelling venous catheter, bone marrow
aspiration,orharvest),thenovariancryopreservationshould
be performed during the same anesthetic session.
A summary of our revised guidelines for oﬀering ovarian
cryopreservation to girls with cancer is presented in Table 2.
Table 2:Revisedguidelinesforoﬀeringovariancryopreservationto
premenarcheal girls with cancer.
The treating team will conduct a detailed discussion of the risks
and potential beneﬁts of ovarian cryopreservation with the
parents/guardians, and, where age-appropriate, with the patient.
Ovarian cryopreservation will be oﬀered in cases where necessary
medical treatments pose a high-risk of ovarian damage (e.g, bone
marrow transplantation, whole-abdomen radiationtherapy, and
alkylator-intensive chemotherapy).
Ovarian cryopreservation will be oﬀe r e dt og i r l so v e r1y e a r so f
age. Below 1 year of age, each case should be assessed individually
in a multidisciplinary discussion (may be modiﬁed with
increasing experience).
Ovarian cryopreservation should preferably be performed during
a medically indicated anesthetic session (insertion of an
indwelling venous catheter, bone marrow biopsy, and autologous
bone marrow harvest).
Medical centers providing pediatric oncology care should form
multidisciplinary teams to oﬀer this treatment.
The ﬁeld of fertility preservation is constantly evolving,
as new experience is acquired and new lessons are learned.
Expertise in performing ovarian tissue cryopreservation and
transplantation is increasing rapidly. We believe that all
considerations and guidelines should be reevaluated and
modiﬁed according to new data, in order to provide the best
beneﬁt-to-risk ratio for the patients.
We strongly believe that there is an ethical obligation
of clinicians to oﬀer fertility preservation and to discuss
fertility issues with cancer patients or their parents, in order
to provide the opportunity for future parenthood.
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